Study Assessing long-teRm Outcomes of dupiluMAb (DUPIXENT) treatment in adult patients with chronic rhinosinusitis with nasal polyposis (CRSwNP)
- Conditions
- Chronic rhinosinusitis with nasal polyposis (CRSwNP)
- Registration Number
- JPRN-jRCT1031210642
- Lead Sponsor
- Administrator Clinical Trials
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 50
1. Patients in or over 18 years at initiation
2. All patients who are newly initiated on DUPIXENT for the treatment of CRSwNP according to the respective prescribing information (Product Label or SmPC)
3. Willing and able to comply with clinic visits and study-related procedures as per protocol
4. Provide informed consent signed by study patient or legally acceptable representative
5. Able to understand and complete study-related questionnaires as per protocol
1. Patients who have a contraindication to DUPIXENT according to the country-specific prescribing information
2. Any previous treatment with DUPIXENT for any condition
3. Any condition that, in the opinion of the investigator, may interfere with the patient s ability to participate in the study per protocol
4. Participation in an ongoing interventional or observational study that might, in the treating physician s opinion, influence the assessments for the current study
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method - Baseline Patient Characteristics <br>- Baseline Disease Characteristics
- Secondary Outcome Measures
Name Time Method